Exscientia Plc (EXAI)

$5.01

-0.2

(-3.84%)▲

Live

Performance

  • $4.98
    $5.22
    $5.01
    downward going graph

    0.6%

    Downside

    Day's Volatility :4.6%

    Upside

    4.02%

    downward going graph
  • $3.80
    $7.91
    $5.01
    downward going graph

    24.15%

    Downside

    52 Weeks Volatility :51.96%

    Upside

    36.66%

    downward going graph

Returns

PeriodExscientia PlcSector (Health Care)Index (Russel 2000)
3 Months
0.58%
3.6%
0.0%
6 Months
22.59%
10.2%
0.0%
1 Year
-5.79%
19.6%
0.0%
3 Years
-75.37%
16.8%
-23.0%

Highlights

Market Capitalization
662.0M
Book Value
$2.33
Earnings Per Share (EPS)
-1.35
Wall Street Target Price
5.35
Profit Margin
0.0%
Operating Margin TTM
-888.82%
Return On Assets TTM
-18.86%
Return On Equity TTM
-36.34%
Revenue TTM
21.0M
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
47.0%
Gross Profit TTM
10.2M
EBITDA
-137.0M
Diluted Eps TTM
-1.35
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.79
EPS Estimate Next Year
-0.83
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Exscientia Plc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 6.79%

Current $5.01
Target $5.35

Company Financials

FY19Y/Y Change
Revenue
15.6M
-
Net Income
-10.8M
-
Net Profit Margin
-69.36%
-
FY20Y/Y Change
Revenue
17.7M
↑ 10.39%
Net Income
-40.8M
↑ 266.64%
Net Profit Margin
-230.39%
↓ 161.03%
FY21Y/Y Change
Revenue
27.0M
↑ 54.17%
Net Income
-48.6M
↑ 20.27%
Net Profit Margin
-179.73%
↑ 50.66%
FY22Y/Y Change
Revenue
32.6M
↑ 31.98%
Net Income
-142.1M
↑ 219.61%
Net Profit Margin
-435.26%
↓ 255.53%
FY23Y/Y Change
Revenue
25.0M
↓ 26.35%
Net Income
-181.8M
↑ 23.0%
Net Profit Margin
-726.94%
↓ 291.68%
Q1 FY23Q/Q Change
Revenue
7.0M
↓ 29.74%
Net Income
-45.7M
↓ 20.08%
Net Profit Margin
-653.41%
↓ 79.02%
Q2 FY23Q/Q Change
Revenue
3.8M
↓ 47.82%
Net Income
-45.4M
↓ 4.44%
Net Profit Margin
-1.2K%
↓ 543.23%
Q3 FY23Q/Q Change
Revenue
11.0M
↑ 195.48%
Net Income
-38.7M
↓ 13.22%
Net Profit Margin
-351.43%
↑ 845.21%
Q4 FY23Q/Q Change
Revenue
6.7M
↓ 40.44%
Net Income
-26.6M
↓ 32.7%
Net Profit Margin
-397.11%
↓ 45.68%
Q1 FY24Q/Q Change
Revenue
5.3M
↑ 0.0%
Net Income
-21.0M
↑ 0.0%
Net Profit Margin
-397.11%
↑ 0.0%
Q2 FY24Q/Q Change
Revenue
4.4M
↓ 16.47%
Net Income
-36.2M
↑ 72.51%
Net Profit Margin
-820.07%
↓ 422.96%
FY19Y/Y Change
Total Assets
71.2M
-
Total Liabilities
33.3M
-
FY20Y/Y Change
Total Assets
142.3M
↑ 94.81%
Total Liabilities
35.1M
↑ 2.79%
FY21Y/Y Change
Total Assets
852.6M
↑ 505.0%
Total Liabilities
98.3M
↑ 182.3%
FY22Y/Y Change
Total Assets
778.6M
↓ 0.19%
Total Liabilities
204.7M
↑ 127.66%
FY23Y/Y Change
Total Assets
652.3M
↓ 19.45%
Total Liabilities
198.0M
↓ 7.02%
Q1 FY23Q/Q Change
Total Assets
731.9M
↓ 23.11%
Total Liabilities
188.7M
↓ 24.59%
Q2 FY23Q/Q Change
Total Assets
712.1M
↓ 6.52%
Total Liabilities
185.2M
↓ 5.72%
Q3 FY23Q/Q Change
Total Assets
682.8M
↓ 2.45%
Total Liabilities
195.0M
↑ 7.16%
Q4 FY23Q/Q Change
Total Assets
599.5M
↓ 13.92%
Total Liabilities
181.0M
↓ 9.03%
Q1 FY24Q/Q Change
Total Assets
601.9M
↑ 0.0%
Total Liabilities
181.7M
↑ 0.0%
Q2 FY24Q/Q Change
Total Assets
556.4M
↓ 7.55%
Total Liabilities
180.1M
↓ 0.85%
FY19Y/Y Change
Operating Cash Flow
12.1M
-
Investing Cash Flow
-2.2M
-
Financing Cash Flow
-250.6K
-
FY20Y/Y Change
Operating Cash Flow
-39.2M
↓ 417.12%
Investing Cash Flow
-5.0M
↑ 120.42%
Financing Cash Flow
103.1M
↓ 40188.77%
FY21Y/Y Change
Operating Cash Flow
-6.6M
↓ 83.08%
Investing Cash Flow
-35.3M
↑ 609.37%
Financing Cash Flow
525.7M
↑ 414.94%
Q1 FY23Q/Q Change
Operating Cash Flow
-52.6M
↓ 25.43%
Investing Cash Flow
116.2M
↑ 0.0%
Financing Cash Flow
-885.7K
↓ 27.27%
Q2 FY23Q/Q Change
Operating Cash Flow
-52.1M
↓ 4.86%
Investing Cash Flow
120.9M
↑ 0.0%
Financing Cash Flow
-1.1M
↑ 19.59%
Q3 FY23Q/Q Change
Operating Cash Flow
-42.4M
↓ 17.25%
Investing Cash Flow
-130.9M
↓ 210.14%
Financing Cash Flow
-1.1M
↑ 5.27%

Technicals Summary

Sell

Neutral

Buy

Exscientia Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Exscientia Plc
Exscientia Plc
3.37%
22.59%
-5.79%
-75.37%
-80.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Exscientia Plc
Exscientia Plc
NA
NA
NA
-0.79
-0.36
-0.19
NA
2.33
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Exscientia Plc
Exscientia Plc
Buy
$662.0M
-80.77%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Exscientia Plc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 8.88M → 4.41M (in $), with an average decrease of 19.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -21.00M → -36.23M (in $), with an average decrease of 72.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 79.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 120.2%

Institutional Holdings

  • Novo A/S

    10.30%

  • SoftBank Group Corp

    4.47%

  • LAURION CAPITAL MANAGEMENT LP

    4.05%

  • Baillie Gifford & Co Limited.

    3.46%

  • Junked Platinum Investment Management Ltd

    1.52%

  • First Trust Advisors L.P.

    1.36%

Company Information

at the forefront of small molecule drug discovery we are the first company to automate drug design, surpassing conventional human endeavour. our ai driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. with better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, adme and other key criteria. from this, a selection of the best, information-rich compounds are selected for synthesis and assay. with new experimental data generated, the results are integrated and the next design cycle initiated. rapid design-make-test cycles ensure unparalleled progress towards desired project goals. exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Organization
Exscientia Plc
Employees
483
CEO
Dr. David Hallett Ph.D.
Industry
Healthcare

Discover More

FAQs